Michael Levitz is a strategic, execution-driven Chief Financial Officer with more than 20 years of public- company medical device experience, including over a decade as CFO leading global, high-growth organizations. Recognized for driving enterprise value, operational excellence, and investor confidence at companies such as Insulet Corporation in diabetes care, Michael combines financial acumen with strategic vision. As a trusted advisor and values-based leader, Michael brings deep experience in finance, corporate governance and organizational performance, along with a passion for advancing medical innovation and empowering high-impact teams. In addition to serving on the board and as chairman of the audit committee of Kandu Inc., Michael is president of PTP Advisory LLC and serves on the advisory board of Thirdwayv Inc. Michael began his career in the high-technology audit practice of Arthur Andersen, is a certified public accountant, and has a degree in business economics with emphasis in accounting from the University of California at Santa Barbara.
Archives: Team Showcase
Post Type Description
Bret Christinsen
Bret Christensen is a seasoned leader recognized for his exceptional ability to launch innovative solutions, penetrate markets and effectively scale businesses. With over two decades of experience in the healthcare sector, a specialized focus on women’s health and a comprehensive understanding of the broader healthcare landscape, Bret has consistently proven his ability to elevate emerging solutions into market share leaders, solidifying his reputation as a catalyst for growth and success.
Over the course of his distinguished career, Bret has held strategic commercial and general management leadership roles at Hologic (NASDAQ: HOLX), Myriad Genetics (NASDAQ: MYGN) and Insulet (NASDAQ: PODD), where he played a central role in revolutionizing treatments in women’s health care, oncology and diabetes, respectively. His strategic leadership drove significant revenue growth, achieved product commercialization success and advanced groundbreaking therapies that have redefined standards of care.
Bret’s expertise spans diagnostics, therapeutics and medical devices, positioning him as the ideal leader to accelerate Biote to its next level of growth. With a rare blend of business acumen and deep industry insight, he is uniquely equipped to drive Biote’s continued success as a leading educator in hormone optimization and therapeutic wellness while expanding its market presence and reach.
Bret holds a Bachelor of Science from Utah Valley University, a Masters of Business Administration from the University of Utah, David Eccles School of Business and several executive certifications from the University of Chicago Booth School of Business.
William Tai
William Tai is a successful entrepreneur and investor with over 30 years of experience in the technology industry. He is the Founder and Managing Partner of Amed Ventures, a San Francisco Bay Area-based venture capital fund focused on Medical Device and Medical Technologies investments. He is also the former VP of Business Development at CTBC Bank Corp. William has earned a Bachelor’s Degree in Finance from National Chengchi University and an MBA from Baruch College.
Kevin Reilly
Kevin Reilly joined Ally Bridge Group in 2021 and is a Managing Director, Head of Medtech, for the private equity strategy, focused on transactions across healthcare subsectors. Before joining Ally Bridge Group, Kevin was a Principal at CRG, a healthcare investment management firm providing growth capital to companies through the form of long-term debt and equity. Kevin began his career in the Healthcare Investment Banking Group at Stifel. Kevin holds a B.S. in Finance and Information Systems from the University of Maryland.
Leo Petrossian
Dr. Leo Petrossian is the Chief Executive Officer of Kandu Inc., a neurotechnology company formed from the merger of Neurolutions and Kandu Health. He is a seasoned healthcare executive and entrepreneur with deep expertise in bringing transformative medical devices from early development to commercialization. Under his leadership, Neurolutions pioneered the IpsiHand®, the first FDA-cleared brain–computer interface for stroke rehabilitation. Dr. Petrossian is passionate about advancing technologies that expand access, improve outcomes, and reshape standards of care in neurology and beyond.
Dr. Petrossian earned his MBA from the UCLA Anderson School of Management in 2014 and earned his Ph.D. & MS in Biomolecular Nanotechnology & Solid-State Device Physics as an NSF IGERT fellow at Arizona State University in 2007. He also holds a double B.S. in Electrical Engineering & Biomedical Engineering from California State University, Long Beach.
Fred Khosravi
Fred Khosravi is a Silicon Valley medical device entrepreneur with over 30 years of experience in medical technology, including management and executive positions in both large and small enterprises. He has co-founded Incept LLC and serves as its managing director, focusing on technology innovation and entrepreneurship in the life-sciences field and occasionally extending to information technology. Fred is credited as an inventor or co-inventor on over 200 patents and patent applications globally, holds degrees in mechanical engineering from Tennessee Tech University, and is involved in various organizations such as the Center for Strategic and International Studies, Spirit of America, and Technology for America.
Tudor Jovin, MD
Internationally acclaimed neurologist and researcher, Tudor G. Jovin, MD, is based at Cooper University Hospital in Camden, New Jersey, and presides as the Chief and Chairman of Cooper Neurological Institute. Dr. Jovin is an expert in the interventional and non-interventional treatment for the entire spectrum of stroke and cerebrovascular disorders. He was one of the nation’s first interventional neurologists, a medical subspecialty that uses minimally invasive technologies applied from within the vessels to diagnose and treat diseases of the arteries and veins of the head, neck, and spine such as acute stroke, carotid stenosis, intracranial aneurysm, and arteriovenous malformations. In addition to his clinical experience, Dr. Jovin is known internationally for his research activities. He has served as principal investigator for several international clinical studies, including REVASCAT, a randomized trial of endovascular therapy versus medical therapy for acute stroke within eight hours of symptoms onset conducted in Spain, and DAWN, a multicenter, international, randomized trial of endovascular therapy versus medical therapy in the beyond eight-hour time window. Both studies are considered landmark studies in the development of treatments for acute stroke and have been published in the New England Journal of Medicine. He is a member of the executive or steering committees for several multicenter national and international trials, and has participated as site principal investigator or co-investigator in multiple national and international trials. Additionally, he serves as editorial board member for numerous medical journals. Dr. Jovin has published more than 300 articles in peer-reviewed journals or book chapters. The consequential nature of his research is evidenced by recently published studies that have identified Dr. Jovin as the highest impact author in the neuro-interventional field. Prior to joining Cooper, Dr. Jovin was a professor of neurology and neurosurgery at the University of Pittsburgh School of Medicine and director of the Center for Neuroendovascular Therapy at the University of Pittsburgh Medical Center (UPMC). At UPMC, he also served as the director of UPMC’s Stroke Institute, one of the leading centers for stroke care, education, and research in the world.
Eric Leuthardt, MD
Eric C. Leuthardt, M.D. is a highly regarded neurosurgeon and professor at Washington University in St. Louis. He holds positions in several departments, including Neurological Surgery, Neuroscience, Biomedical Engineering, Mechanical Engineering, and Material Sciences, and serves as the Chief of the Division of Neurotechnology. Leuthardt is known for his innovative research in the field of neuroprosthetics, neurotechnologies, advanced brain imaging, and neurosurgical devices.
His work has earned him recognition as a pioneer in applied neuroscience and he has over 1800 patents filed with the US Patent and Trademark Office for various medical devices and brain-computer interface technologies. In addition to his academic and research achievements. He is also a successful entrepreneur, having founded eight startup companies. He is an Emmy Award-winning playwright and the author of two fiction novels.
Nancey Trevanian Tsai, MD
Nancey Trevanian Tsai, MD is a Diplomate of the American Board of Physical Medicine and Rehabilitation. She is the Associate Program Director of the HCA Trident Healthcare PM&R Residency, Eta Kappa Nu, Senior Member, and Chair of the South Carolina section of the IEEE. She has served as a past Chair of the American Council on Exercise and past Chair of the South Carolina Medical Association Young Physicians Section. She has a patent for the Blink Reflexometer in Australia and Japan, and the United States. She is a mother, a musician, and a former Olympic athlete and coach.
Seth Wilk
Seth Wilk is the Chief Innovation Officer at Kandu, Inc., with 20 years of experience in research, development, and intellectual property. He has authored over 100 publications and patents, secured more than $50M in federal grant funding, and led multiple clinical studies and trials. Dr. Wilk earned his PhD and MS in Biomolecular Nanotechnology as an NSF IGERT Fellow at Arizona State University in 2005, and holds a BS in Electrical Engineering from The College of New Jersey.
